Our recent executive appointment of Dr James Winkler and the PTX pipeline could make us a future target.
"Dr Winkler held senior leadership positions with pioneering targeted cancer drug developer Array BioPharma (NASDAQ: ARRY; Array) where he established and led the Company’s licensing and collaboration efforts. At Array, Dr Winkler provided leadership for multiple teams working in drug discovery, translational research and clinical development, as well as managing several collaborations with multinational pharmaceutical firms.
He helped build an impressive pipeline of development drugs with over 12 advancing toward Phase II or III studies. Array BioPharma has engaged in cancer drug collaborations with Pfizer and Merck and in 2013 entered a multi-year licensing and collaboration partnership with Loxo Oncology (NASDAQ: LOXO) to develop a number of promising new small molecule cancer drugs.
Most recently Dr Winkler served as Vice President Discovery and Translational Biology with drug discovery and development company FORMA Therapeutics and Chief Scientific Officer with Arvinas Inc (NASDAQ: ARVN). Dr Winkler also worked with GlaxoSmithKline as Associate Director, Department of Oncology Research.
